GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans

Abstract

Muscle microvascular surface area determines substrate and hormonal exchanges between plasma and muscle interstitium. GLP-1 (glucagon-like peptide-1) regulates glucose-dependent insulin secretion and has numerous extrapancreatic effects, including a salutary vascular action. To examine whether GLP-1 recruits skeletal and cardiac muscle microvasculature in healthy humans, 26 overnight-fasted healthy adults received a systemic infusion of GLP-1 (1.2 pmol/kg of body mass per min) for 150 min. Skeletal and cardiac muscle MBV (microvascular blood volume), MFV (microvascular flow velocity) and MBF (microvascular blood flow) were determined at baseline and after 30 and 150 min. Brachial artery diameter and mean flow velocity were measured and total blood flow was calculated before and at the end of the GLP-1 infusion. GLP-1 infusion raised plasma GLP-1 concentrations to the postprandial levels and suppressed plasma glucagon concentrations with a transient increase in plasma insulin concentrations. Skeletal and cardiac muscle MBV and MBF increased significantly at both 30 and 150 min (P<0.05). MFV did not change in skeletal muscle, but decreased slightly in cardiac muscle. GLP-1 infusion significantly increased brachial artery diameter (P<0.005) and flow velocity (P=0.05) at 150 min, resulting in a significant increase in total brachial artery blood flow (P<0.005). We conclude that acute GLP-1 infusion significantly recruits skeletal and cardiac muscle microvasculature in addition to relaxing the conduit artery in healthy humans. This could contribute to increased tissue oxygen, nutrient and insulin delivery and exchange and therefore better prandial glycaemic control and tissue function in humans.

Figures

Figure 1. GLP-1 infusion significantly increased skeletal muscle MBVand MBF

Each subject received a systemic infusion of GLP-1 at 1.2 pmol/kg of body mass per min. (A) MBV. (B) MFV. (C) MBF. Results are means±S.E.M. *P<0.001, **P<0.04 and ***P<0.008 compared with baseline.

Figure 2. GLP-1 infusion significantly increased cardiac muscle MBVand MBF

Each subject received a systemic infusion of GLP-1 at 1.2 pmol/kg of body mass per min. (A) MBV. (B) MFV. (C) MBF. Results are means±S.E.M. #P < 0.001 and ##P< 0.003 compared with baseline.